In rats bearing an intracranial T9 glioma, immunization with tumor antigens induces myeloid suppressor cells, which express neutrophil (His48) and monocyte (CD11bc) markers, to infiltrate the tumors. The His48 + /CD11bc + cells were not derived from CNS microglia but were hematogenous; suppressed multiple T cell effector functions; and are myeloid-derived suppressor cells (MDSC). The glioma-infiltrating MDSC expressed arginase I, iNOS, indoleamine 2,3-dioxygenase and TGF-β; however, inhibitor/blocking studies demonstrated that NO production was the primary mechanism of suppression which induced T cell apoptosis. These findings suggest that neuro-immunomodulation by MDSC in rat gliomas maybe mediated by a pathway requiring NO production.
Introduction
Glioblastomas are grade IV astrocytic neoplasms derived from the glial lineage; represent ∼50% of primary central nervous system tumors; and are essentially incurable with a median survival of approximately 18 months after primary diagnosis (Surawicz et al., 1998) . Current standard treatment is surgical debulking followed by concomitant temozolomide chemotherapy and radiotherapy which has shown to extend median survival and additional 2.5 months (Stupp et al, 2009) . Many brain tumor researchers believe that the development of a glioma vaccine, which can activate glioma-specific T cells, would be an effective compliment to current treatment and could be used to destroy residual tumor cells and prevent recurrence. Immunization strategies to include tumor cells that have been genetically altered to secrete immune enhancing cytokines; dendritic cells that have been manipulated to present tumor antigens; and active immunization with recombinant cancer peptides (reviewed by Luptrawan et al., 2008; Okada and Pollack, 2004; Selznick et al., 2008) . However, because of the immunosuppressive environment of the brain tumor, these approaches have met with little success. Malignant gliomas produce soluble factors such as transforming growth factor (TGF)-β, prostaglandins and interleukin (IL)-10 which are part of the immunosuppressive tumor environment (reviewed in Gomez and Kruse, 2006) . Immunomodulating cells which also suppress T cells function are found to infiltrate gliomas, such as T regulatory cells, macrophages and microglial (reviewed in Sonabend et al., 2008; Watters et al., 2005) . More recently, we and others have identified immuno-regulatory myeloid cells that infiltrate experimental rodent brain tumors (Prins et al., 2002; Thomas et al., 2008) . These tumor infiltrating myeloid cells are phenotypically double positive for granulocyte and monocyte markers, His48/CD11bc (rat) or Gr1/CD11b (mouse). It has yet to be determined if these tumor-associated, regulatory cells represent a population of: myeloid-derived suppressor cells (MDSC); immature-regulatory dendritic cells; or microglial cells (Cools et al., 2007; Nagaraj and Gabrilovich, 2007; Watters et al., 2005) .
The generation of MDSC has been generally reported in non-glial, murine tumor models. However, there are also studies of MDSC in other pathological settings such as experimental autoimmune encephalomyelitis, graft-vs-host disease, bacterial infections and severe trauma models in which down-modulation of T cell activity is a common feature (al Ramadi et al., 1991; Bobe et al., 1999; Makarenkova et al., 2006; Zhu et al., 2007) . Human MDSC have been recently described in cancers such as melanoma and in renal cell carcinoma (Filipazzi et al., 2007; Ko et al., 2009; Zea et al., 2005) .
There are multiple mechanisms by which MDSC exert their regulatory effects on activated T cells some of which include the catabolism of essential amino acids such as tryptophan or arginine by indoleamine 2,3-dioxygenase (IDO) or arginase 1, respectively; production of nitric oxide (NO); or by the production of immunosuppressive cytokines such as TGF-β (Mazzoni et al., 2002; Mellor and Munn, 2004; Rodriguez and Ochoa, 2008; Xiang et al., 2008) . Immature dendritic cells and regulatory microglia have been reported to down-modulate T cell activity by the production of TGF-β (Gandhi et al., 2007; Watters et al., 2005) . 
